Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Net Cash Flow (2022 - 2025)

BioXcel Therapeutics (BTAI) has 4 years of Net Cash Flow data on record, last reported at $18.7 million in Q3 2025.

  • For Q3 2025, Net Cash Flow rose 218.01% year-over-year to $18.7 million; the TTM value through Sep 2025 reached -$3.1 million, up 93.81%, while the annual FY2024 figure was -$35.4 million, 72.48% up from the prior year.
  • Net Cash Flow reached $18.7 million in Q3 2025 per BTAI's latest filing, up from -$12.4 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $18.7 million in Q3 2025 and bottomed at -$38.6 million in Q4 2022.
  • Average Net Cash Flow over 4 years is -$17.5 million, with a median of -$17.9 million recorded in 2024.
  • Peak YoY movement for Net Cash Flow: plummeted 3202.64% in 2023, then surged 218.01% in 2025.
  • A 4-year view of Net Cash Flow shows it stood at -$38.6 million in 2022, then surged by 35.89% to -$24.7 million in 2023, then skyrocketed by 57.43% to -$10.5 million in 2024, then skyrocketed by 277.96% to $18.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Cash Flow were $18.7 million in Q3 2025, -$12.4 million in Q2 2025, and $1.2 million in Q1 2025.